New research finds that nicotine salts, like nicotine, are safe for the vast majority of people.
The study, which was published in the Journal of the American Medical Association, was conducted by researchers at the University of North Carolina at Chapel Hill and the University at Buffalo.
The findings, published in JAMA Internal Medicine, also found that nicotine salt was associated with less serious adverse events, such as lower blood pressure and a reduction in risk of heart disease.
“We are in the midst of a new era of pharmaceutical development, where the need for nicotine replacement therapies is increasing and our understanding of how these medications work and how they interact is growing,” said lead author Dr. Michael W. Smith, associate professor of medicine at UNC-Chapel Hill.
“This research provides evidence to support a position that nicotine is safe in the short term, but over time, may be associated with adverse events that are difficult to manage and prevent.”
The researchers analyzed the drug’s safety profiles from two different types of studies.
One type examined how long a person’s intake of the drug increased over time.
This study found that the daily dose of nicotine salt for a typical person was about 50 milligrams, or about four to six times the amount of nicotine that is found in a cigarette.
This dosage is typically found in cigarette packages, but it is less common for many other products.
The other type examined the effects of a high dose of the substance, and found that a daily dose was about 150 milligram, or nearly three times the daily dosage found in the nicotine packet.
A person who had smoked at least 10 cigarettes per day for at least three years had a daily intake of about 8 milligraphic (mg) of nicotine, or roughly five times the recommended daily dose.
A smoker who had been abstinent for at most three years was found to have a daily exposure of about 3 mg of nicotine.
The researchers also found nicotine was not associated with any other adverse effects.
The average daily dose for smokers was about 0.25 mg of the compound.
Nicotine was found in approximately 1 percent of the cigarette packages that were tested, according to the study.
The number of studies that examined the compound is low, said Dr. Daniel W. Brown, an associate professor in the Department of Clinical Pharmacology and Toxicology at the Icahn School of Medicine at Mount Sinai and the author of the study that led to the new research.
Brown is the lead author of a study published last year in the journal Pharmacology.
He also was not involved in the new study.
“The problem is, we don’t have good quality studies of the drugs, and we don-t have a good number of people who have tested the drugs,” he said.
The latest study was a meta-analysis of a total of over 20 studies, which looked at a variety of drugs, Brown said.
“Some of the studies were small, but some were large,” he added.
“It’s hard to compare the results of small studies with large ones.”
Dr. Stephen F. Hsu, a professor of clinical pharmacology and toxicology at Duke University School of Pharmacy, is not a part of the new UNC-Buffalo study, but he did review it.
“In the small studies, nicotine is associated with a small amount of adverse events,” he told The Associated Press.
“But we have a lot of studies on other drugs.
So it’s a little bit more complicated to compare it to tobacco because tobacco is much more dangerous than nicotine.”
While there are many different forms of nicotine in cigarette smoke, Hsu said, “the nicotine in a nicotine-containing pack tends to be much more toxic than the nicotine in the pack of a nicotine liquid.”
Hsu added that, in the large studies, the drugs were associated with lower doses of nicotine exposure.
However, he said, the risk of adverse effects may be similar for the drug in the liquid form, such that the doses are not very different.
In a small study of 20 people, Hsiuc reported that a person with a high intake of nicotine had a 2.4 times greater risk of death from any cause and a 3.3 times greater death risk from cancer than a person who didn’t smoke.
The authors of the current study found a similar trend.
“These data are reassuring,” Hsu told The AP.
“People should know that the use of nicotine is not necessarily a bad thing.
In fact, the use can be beneficial in some circumstances.”
The new findings also show that the nicotine is also linked to other conditions.
Hsiu said people who had previously smoked cigarettes had higher levels of inflammation and liver disease, compared with non-smokers.
“For example, there are a lot more inflammation markers in smokers compared to non-smoking people,” Hsiust said.
But the authors of that study also noted that there is no link between cigarette smoking and heart disease